OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

• Status: Completed
• Trial end date: 2006-02-01

Summary

This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.

• Phase: Phase 3

Details

• Lead Sponsor: GlaxoSmithKline
• Collaborator: Sanofi
• Treatments: Fondaparinux; PENTA